TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Conversations as a Means to Delay the Onset of Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Non-demented participants~* Willing to participate in daily conversation using internet/webcam with interviewers for 6 weeks~* Willing to monitor daily conversational amount using a digital recording device~* Willing informant who has frequent contact with the participant~Exclusion Criteria:~* have major illness or disabilities which interfere with interacting using the audio/video technology~* diagnosed as dementia~* MMSE \< 24 at screening~* Geriatric Depression Scale (15 items) \>4 at screening

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control group (Type: PLACEBO_COMPARATOR): No daily conversational sessions with interviewers using webcam/internet. Weekly web-based heath form must be submitted using internet/PC. If not, subjects receive prompts from study personnel.
- Active social engagement group (Type: ACTIVE_COMPARATOR): Engage in 30 minutes video chat daily (5 times per week, except weekend) with interviewers for 6 weeks. Weekly web-based heath form must be submitted using internet/PC. If not, subjects receive prompts from study personnel.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Compare the Pharmacokinetics of NVP-1205 and Coadministration of Rosuvastatin and Ezetimibe

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male subjects age between 19 and 55 signed informed consent~Exclusion Criteria:~* subjects have a history of allergy reaction of this drug or other drugs

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- NVP-1205 (Type: EXPERIMENTAL): administration of NVP-1205(rosuvastatin+ezetimibe)
- rosuvastatin and ezetimibe (Type: ACTIVE_COMPARATOR): coadministration of rosuvastatin and ezetimibe

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab and Radiation Therapy for Sarcomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Primary soft tissue sarcoma (STS) or an isolated local recurrence of STS. Open incisional biopsy or core biopsies should be performed within 8 weeks prior to registration~* Tumor grade of intermediate or high grade~* Tumor must be located on the upper extremity, the lower extremity, trunk, retroperitoneum, or pelvis~* Primary tumors must be \> 5.0cm in maximal diameter and local recurrence can be any size~* 18 years of age or older~* Zubrod performance status of 0-2~* Adequate organ and marrow function~Exclusion Criteria:~* Metastatic disease~* Pregnant or lactating women~* HIV positive patients~* Prior treatment with radiation, chemotherapy or biotherapy for this tumor~* History or evidence of central nervous system (CNS) disease~* Serious, non-healing wound, ulcer, or bone fracture~* Clinically significant cardiovascular disease, New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, or Grade II or greater peripheral vascular disease within 1 year~* History of stroke within the past 6 months~* Major surgical procedure or significant traumatic injury within 28 days~* Current or recent (within 10 days) use of full-dose oral or parenteral anticoagulants or thrombolytic agents.~* Presence of bleeding diathesis or coagulopathy~* Proteinuria at baseline or clinically significant impairment of renal function~* History of abdominal fistula, gastrointestinal perforation, or inta-abdominal abscess within the past 6 months~* Documented history of uncontrolled seizures~* Grade 2 or greater sensory neuropathy based upon the NCI CTCAE, version 3.0~* Known history of deep vein thrombosis or pulmonary embolus~* Known hypercoagulable disorder~* History of hepatic cirrhosis or current hepatic dysfunction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab, Radiation, and Surgery (Type: EXPERIMENTAL): Bevacizumab 5mg/kg, external beam radiation therapy (XRT), surgery, Intraoperative radiation therapy (IORT), and postoperative external beam radiation therapy (Post-op XRT)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neuromodulation of Conscious Perception: Investigating Thalamic Roles Through Ultrasonic Stimulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be right-handed.~* Must have normal or corrected-to-normal vision (while wearing contact lenses). Please note: persons who need eyeglasses to achieve 20/20 vision cannot be included in this study as eyeglasses cannot be worn during the study visit.~* Must not be on any medications for any neurological, psychological, or psychiatric conditions.~* Must be English speaking.~* Must be capable of giving written informed consent.~Exclusion Criteria:~• Vision that is not 20/20, or vision that is not corrected to 20/20 while wearing contact lenses.~Please note: persons needing eyeglasses to achieve 20/20 vision cannot be included in this study as eyeglasses cannot be worn during the study visit.~* History of significant head injury with loss of consciousness.~* Learning disability or other developmental disorder.~* Medication use for any neurological, psychological, or psychiatric conditions.~* Any impairment (sensory or motor loss), activity, or situation that in the judgment of the study coordinator or Principal Investigators would prevent satisfactory completion of the study protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- LIFUP excitation (Type: EXPERIMENTAL): The study will involve the enrollment of 60 participants, who will be randomly assigned to two groups, with each group consisting of 30 participants. The participants will be divided based on the type of transcranial LIFUP they will receive, either excitation or inhibition, targeting four specific thalamic areas.
- LIFUP inhibition (Type: EXPERIMENTAL): The study will involve the enrollment of 60 participants, who will be randomly assigned to two groups, with each group consisting of 30 participants. The participants will be divided based on the type of transcranial LIFUP they will receive, either excitation or inhibition, targeting four specific thalamic areas.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Identification of their main symptom as heartburn defined as a burning feeling behind the breastbone.~* Have at least a 6-month history of heartburn and at least 4 days of episodes of heartburn with at least overall moderate intensity during the last 7 days prior to visit 1.~* Erosive esophagitis according to LA classification Grade A, B, C or D, at the visit 1 endoscopy.~* Have provided Informed consent.~Exclusion Criteria:~Subjects with current or historical evidence of the following conditions are excluded from the study:~* Esophageal stricture.~* Primary esophageal motility disorder(s), i.e. diffuse esophageal spasm, achalasia.~* Systemic Sclerosis (scleroderma).~* Irritable Bowel Syndrome (IBS), i.e. upper abdominal discomfort or pain that in the opinion of the Investigator is likely to be due to IBS or fulfilling two or more of the criteria: relieved by defecation, associated with change in frequency of stools, associated with change in form (appearance) of stools.~* Inflammatory bowel disease.~* Zollinger-Ellison syndrome.~* Gastric ulcer, duodenal ulcer or duodenal erosions within the last 3 months~Subjects with i) history of significant or ii) current significant or unstable:~* Cardiovascular diseases or cardiac chest pain.~* Cerebrovascular diseases, such as cerebral ischemia, infarction, haemorrhage, or embolus.~* Diabetes mellitus. Stable diabetes controlled on diet, oral agents or insulin is acceptable.~* Pulmonary, renal, pancreatic or liver diseases or any other serious disease as judged by the investigator to interfere with the evaluation of the current study.~* Malignant disease (except for minor superficial skin disease).~* Generalised bleeding disorders.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Caregiver Training to Prevent Konzo Disease in Children in Democratic Republic of Congo (DRC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Mother with at least one child aged between 1 and 4 years~* Mother is the primary caregiver of child~* Mother is 18 years of age or older~Exclusion Criteria:~* History of brain injury (infectious, traumatic, birth) in child~* Konzo disease in any family member of household~* Epilepsy in child~* Any neurodisability in child~* Caregiver is unable to participate in the year-long training

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 4 Years
- Healthy Volunteers: t

Study Arms:
- MISC and WTM (Type: EXPERIMENTAL): Wetting method (WTM)+ Mediational Intervention for Sensitizing Caregivers (MISC) bi-weekly for 12 months.
- WTM only (Type: ACTIVE_COMPARATOR): WTM trainings only (recommended standard of care) bi-weekly for 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
MAIN ELIGIBILITY CRITERIA~* Histologically proven metastatic adenocarcinoma of colon or rectum~* Documented inoperable disease (i.e., not suitable for complete carcinological surgical resection)~* Measurable lesion as assessed by CT scan or MRI in at least one dimension (longest diameter to be recorded) ≥ 20 mm with conventional CT scan or ≥ 10 mm with spiral CT scan~* No previous therapy for metastatic disease~* No history or evidence upon physical examination of CNS disease (e.g., non-irradiated CNS metastasis, seizure not controlled with standard medical therapy, or history of stroke) unless adequately treated~* No exclusive bone metastasis~* ECOG performance status 0-2~* WBC ≥ 1,500/mm\^3~* Platelets ≥ 100,000/mm\^3~* Hemoglobin \> 9 g/dL (may be transfused to maintain or exceed this level)~* Proteinuria \< 2+ by dipstick OR ≤ 1 g of protein on 24-hr urine collection~* Bilirubin \< 1.5 times ULN~* Alkaline phosphatase \< 3 times ULN~* No peripheral sensory neuropathy~* Negative pregnancy test~* Fertile patients must use effective means of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly, or surgically sterilization)~* No peripheral neuropathy ≥ grade 1~* No clinically significant (i.e. active) cardiovascular disease~* No evidence of bleeding diathesis or coagulopathy~* No serious, non-healing wound, ulcer, or bone fracture~* No significant ophthalmologic abnormality~* More than 28 days since prior major surgical procedure or open biopsy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- bevacizumab alone (Type: ACTIVE_COMPARATOR): None
- Bevacizumab + erlotinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \>/= 65 years old~* documented diagnosis of lung, breast, or ovarian cancer, or NHL~* scheduled to receive one of 15 standard chemotherapy regimens~* chemotherapy naive OR have received adjuvant therapy AND/OR have no more than one regimen of chemotherapy for metastatic disease~* life expectancy of at least 3 months~* ECOG performance status \</=2~* adequate renal and hematologic function~* informed consent for participation in the study prior to any study specific procedures~Exclusion Criteria:~* known hypersensitivity to any of the products to be administered during dosing~* primary prophylactic antibiotics in all cycles~* prior radiation therapy within 2 weeks of randomization into this study or plan for radiation therapy during study participation, except for spot radiation for bony metastases~* prior bone marrow or stem cell transplant or plan to receive any transplant therapy during study participation~* clinically symptomatic brain metastases~* Folstein mini-mental state exam score \<18~* Any premalignant myeloid condition or any malignancy with myeloid characteristics~* History of prior malignancy within the last 5 years other than subject's original cancer diagnosis listed in inclusion criteria with the exception of curatively treated basal cell carcinoma, squamous cell carcinoma, in situ cervical carcinoma or surgically cured malignancies~* unstable/uncontrolled cardiac conditions or hypertension~* active infection~* subject is currently enrolled or has not yet completed at least 30 days since ending other investigational device or drug trial or is receiving other investigational agents

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Group 1 (Primary Prophylaxis) (Type: EXPERIMENTAL): Neulasta 6mg single administration per cycle of chemotherapy starting with cycle 1
- Treatment Group 2 (Secondary Prophylaxis) (Type: ACTIVE_COMPARATOR): Per Investigator's discretion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nilotinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Part A:~* Adult patients who have received allo-HSCT~* Performance status ECOG 0-2~* Patients with CMV reactivation (defined as plasma CMV DNA copy numbers of more than 1000 copy numbers/ml by Quantitative-PCR) after allo-HSCT.~* Patients with CMV reactivation that is uncontrollable by conventional first line agent (ganciclovir) for 2 or more weeks, or patients who are intolerable to ganciclovir treatment.~Part B~* Adult patients who have received allo-HSCT~* Performance status ECOG 0-2~* Either the patient or his/her donor are CMV-IgG test positive~* Patients with post-transplantation engraftment: stable myeloid engraftment (absolute neutrophil count 500/mm3) for at least 3 consecutive days, and stable megakaryocyte engraftment (platelet count 20k/uL) for at least 3 consecutive days.~* Patient with no CMV reactivation before enrollment: a negative (undetectable) plasma CMV DNA Quantitative-PCR assay on blood collected within 7 days Patients without previous or current exposure to any prophylactic or therapeutic drugs for CMV reactivation~Exclusion Criteria:~* Patients with renal insufficiency: serum creatinine \> 2.5 mg/dL,~* Patients with significant electrolyte deficiency after suitable supplement: \[K\] \<3.0mmol/L, \[Ca\]\< 2.0 mmol/L(corrected), or \[Mg\] \< 0.6 mmol/L.~* Patients with hepatic dysfunction: alkaline phosphatase ≥2.5 times of the upper normal limit of the normal range (ULN); serum alanine or aspartate aminotransferase levels of \> 5 times ULN; a serum total bilirubin of \> 3 mg/dL~* Patients with serum amylase and lipase \> 1.5 x ULN~* Patients with history of HIV infection~* Patients with unstable medical condition or any other history of serious/significant medical diseases deemed not appropriate to be included to this study as judged by investigators~* Females patient who are pregnant or breast-feeding~* Female patients of childbearing potential not using any reliable and appropriate contraception method(s)~* Patients with life expectancy, as judged by the investigators, is less than 3 months~* Patients with, as judged by the investigators, other contraindications of nilotinib administration, such as prolonged QTc, concurrent usage of drugs that possess possible severe drug-drug interactions with nilotinib, or had severe adverse effects in the previous exposure to nilotinib~* Patients who cannot swallow capsules.~* Patients who are unwilling or unable to give consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nilotinib (Type: EXPERIMENTAL): Single arm, open label study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Trial of the ALK HDM Tablet in House Dust Mite Allergic Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A history of house dust mite induced asthma~* Use of inhaled corticosteroids (ICS)~* Positive skin prick test to house dust mites~* Positive specific IgE to house dust mites~Exclusion Criteria:~* FEV1 lower than 70%

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age of ≥ 18 and ≤ 65 years.~2. Confirmed diagnosis of chronic primary immune thrombocytopenia (ITP) (diagnosed with a threshold platelet count \< 100x10\^9/L) of at least 12 months duration.~3. Platelet count of no more than 20x10\^9/L with or without bleeding manifestations.~4. Freely given written informed consent from patient.~5. Women of childbearing potential must have a negative result on a pregnancy test (human chorionic gonadotropin \[HCG\]-based assay) and need to practice contraception using a method of proven reliability for the duration of the study.~Exclusion Criteria:~1. Thrombocytopenia secondary to other diseases (such as acquired immunodeficiency syndrome \[AIDS\] or systemic lupus erythematosus \[SLE\]), or drug-related thrombocytopenia.~2. Administration of intravenous immunoglobulin (IGIV), anti-D immunoglobulin or thrombopoietin receptor agonists, or other platelet enhancing drugs (including immunosuppressive or other immunomodulatory drugs) within 3 weeks before enrollment, except for:~   * Long-term corticosteroid therapy when the dose has been stable during the preceding 3 weeks and no dosage change is planned until study Day 22.~  * Long-term azathioprine, cyclophosphamide, or attenuated androgen therapy when the dose has been stable during the preceding 3 months and no dosage change is planned until study Day 22.~3. Unresponsive to previous treatment with IGIV or anti-D immunoglobulin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- NewGam (Type: EXPERIMENTAL): Each participant received 1 g/kg NewGam intravenously on 2 consecutive days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study 1 Replication and Extension of Prior Work

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* children with or without a diagnosis of ASD between 18 to 71 months of age~Exclusion Criteria:~* native language is not English~* born premature (\< 36 weeks)~* has uncorrected hearing or vision impairments~* has developmental disorders or medical conditions other than ASD that affect language or cognition (excepting psychiatric conditions often comorbid with ASD such as ADHD)~* has a history of photosensitive epileptic seizures

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: 71 Months
- Healthy Volunteers: t

Study Arms:
- Addressed (Type: ACTIVE_COMPARATOR): Children participate in an interaction with an experimenter who uses the word to be learned.
- Overheard (Type: EXPERIMENTAL): Children are present in the room while an experimenter uses the word to be learned in an interaction with another experimenter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete